A4990712
Icariin , Analysis of standard products, ≥98% , 489-32-7
Synonym(s):
4′-O-methyl-8-γ,γ-dimethylallylkaempferol-3-rhamnoside-7-glucoside
CAS NO.:489-32-7
Empirical Formula: C33H40O15
Molecular Weight: 676.66
MDL number: MFCD00210516
EINECS: 610-440-0
Pack Size | Price | Stock | Quantity |
20MG | RMB66.40 | In Stock |
|
others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
Melting point: | 223-225 ºC |
alpha | D15 -87.09° (in pyridine) |
Boiling point: | 948.5±65.0 °C(Predicted) |
Density | 1.55 |
RTECS | DJ2980500 |
storage temp. | 2-8°C |
solubility | DMSO: soluble50mg/mL, clear, colorless to dark yellow |
form | Powder |
pka | 5.90±0.40(Predicted) |
color | light yellow to yellow |
λmax | 350nm(MeOH)(lit.) |
Merck | 14,3617 |
Stability: | Light Sensitive |
InChIKey | TZJALUIVHRYQQB-XLRXWWTNSA-N |
LogP | 1.736 (est) |
Description and Uses
Icariin has been used:
- in the preparation of topical treatment to determine its effects on the improvement of cutaneous wound healing in rats
- to test its analgesic effects on lower back pain (LBP) in rats
- as a potential treatment in osteoporosis condition in rats
- to study its effects on palmitate (PA)-induced insulin resistance in skeletal muscle C2C12 myotubes
- as a neuroprotective agent to study its effects on amyloid-β (Aβ)-induced neuronal insulin resistance in human neuroblastoma SK-N-MC cells
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319 |
Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
Safety Statements | 24/25 |
WGK Germany | 3 |
HS Code | 29389090 |